当前位置：首页 > 文献互助 > 互助详情

Prevention and treatment of inflammatory arthritis with traditional Chinese medicine: Underlying mechanisms based on cell and molecular targets复制

用户Lz2LyWF0h8HA 1小时前 11 10 已完结

1. 当前求助状态已完结, 请及时下载应助文件

2. 系统将在 2026-04-29 12:01:28 删除文件

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI: 10.1016/j.arr.2023.101981复制

文献链接: https://linkinghub.elsevier.com/retrieve/pii/S156816372300140X复制

其他信息:

出版社: Elsevier BV
作者: Wenhao Li; Lei Yu; Wenming Li; Gaoran Ge; Yong Ma; Long Xiao; Yusen Qiao; Wei Huang; Wenli Huang; Minggang Wei; Zhirong Wang; Jiaxiang Bai; Dechun Geng

上一篇：Updates on the Perioperative Management of Resectable Non–Small Cell Lung Cancer

下一篇：Prevention and treatment of inflammatory arthritis with traditional Chinese medicine: Underlying mechanisms based on cell and molecular targets

互助时间线

2026-04-22 12:03:06 [完结求助]

楼主确认了幸福小屋应助的文件是正确的, 求助状态变成 已完结

2026-04-22 12:01:28 [上传文件]

幸福小屋上传了文件(pdf 7.86 MB), 求助状态变成 待确认

2026-04-22 12:01:02 [发起求助]

最新发布的求助

Yanxiao Di’naer decoction attenuates metabolic dysfunction-associated steatohepatitis through the regulation of gut microbiota and the metabolism of bile acid 34分钟前
Tangeretin formulated in a self-nano-emulsifying drug-delivery system (SNEDDS) alleviates symptoms of rheumatoid arthritis by antagonizing M1 macrophages polarization 1小时前
Prevention and treatment of inflammatory arthritis with traditional Chinese medicine: Underlying mechanisms based on cell and molecular targets 1小时前
Prevention and treatment of inflammatory arthritis with traditional Chinese medicine: Underlying mechanisms based on cell and molecular targets 1小时前
Updates on the Perioperative Management of Resectable Non–Small Cell Lung Cancer 1小时前
HSR26-260: Comparative Efficacy and Safety of Second-Line Therapies in Relapsed Small-Cell Lung Cancer: A Systematic Review and Pooled Analysis 1小时前
Model-based dose selection for phase 3 trials of the selective P2X3 antagonist camlipixant in refractory chronic cough 1小时前
Antibody–Drug Conjugates in Small-Cell Lung Cancer: DLL3, B7-H3, TROP2 and Beyond 1小时前
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial 1小时前
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial 1小时前
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer 1小时前
Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials 1小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com